雷葛氏症候群（LGS）：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

市場概覽

• 預計義大利雷葛氏症候群市場將從 2025 年的 5,000 萬美元成長到 2035 年的 1.1 億美元。
• 以下因素正在推動市場成長：
• 擴大新型抗癲癇療法的應用
• 標靶治療的持續發展
• 未來的發展取決於能夠減少持續性癲癇發作並改善患者預後的治療方法。

雷葛氏症候群（LGS）概述

雷葛氏症候群（LGS）是一種高度嚴重且難治的發育性癲癇性腦病變（DEE），通常發病於嬰兒期，一般在3至5歲之間。此疾病具有通用的表現型特徵，其病因多種多樣，包括腦結構畸形、周產期缺氧缺血性損傷、基因突變或由領先的West症候群（嬰兒期癲癇）進展而來。 LGS的嚴重病理生理特徵是以下三聯徵：多種癲癇發作類型持續混合出現（特別是特異性整體發作、肌張力喪失性「跌倒」發作和非典型失神發作）；中度至重度認知障礙和發育倒退；以及特徵性的發作間期腦電圖（EEG）異常，表現為清醒時瀰漫性慢波棘波複合時間（B33Hz）和整體漫波（B33Hz）。由於持續癲癇發作會導致嚴重的神經認知功能下降，並顯著增加創傷相關併發症和過早死亡的風險，現代治療模式需要積極的多學科合作。治療普遍需要使用頻譜抗癲癇藥物（ASMs）的複雜聯合治療，通常也會加入一些專門用於治療LGS的藥物，例如Clobazam、盧非醯胺或高純度大麻二酚。同時，治療也高度依賴非藥物療法，包括生酮飲食、迷走神經刺激（VNS）和胼胝體切除手術——一種姑息性外科手術，旨在減輕失張力性跌倒發作帶來的毀滅性且危及生命的後果。

主要亮點

• 據預測，德國確診的雷葛氏症候群 (LGS) 病例數將從 2025 年的 6,787 例增加到 2035 年的 6,849 例。
• LGS 是一種罕見嚴重的癲癇性腦病變，其特徵是多種類型的癲癇發作和認知障礙。
• 儘管抗癲癇藥物已經問世，但許多患者仍然遭受難治性癲癇的困擾。
• 目前仍有大量未被滿足的需求，即需要能夠持續抑制癲癇發作並改善生活品質的治療方法。

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物獲得批准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• Epygenix
• Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
• SK Life Science, Inc.
• NeuroPace
• Zogenix, Inc.
• Jazz Pharmaceuticals
• Longboard Pharmaceuticals

目錄

第1章：主要調查結果和分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並正在接受藥物治療的患者族群。
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 目前主要療法－概述及關鍵意見領袖見解
• 新興療法
• 重點
• 值得關注的後期新興療法—概述、市場上市預期和關鍵意見領袖見解
• 值得關注的早期管道

第6章：未滿足的需求與目標產品分析

• 尚未滿足的主要需求及其透過新興療法實現的潛力。
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Lennox-Gastaut Syndrome (LGS) Market Outlook

Thelansis's "Lennox-Gastaut Syndrome (LGS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Lennox-Gastaut Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Lennox-Gastaut Syndrome (LGS) Overview

Lennox-Gastaut syndrome (LGS) is a devastating, highly refractory developmental and epileptic encephalopathy (DEE) that classically manifests in early childhood, typically between the ages of 3 and 5. The disease represents a shared phenotypic endpoint resulting from a highly heterogeneous array of severe underlying etiologies-including structural brain malformations, perinatal hypoxic-ischemic injury, genetic mutations, or evolution from preceding West syndrome (infantile spasms). LGS is fundamentally defined by a pathognomonic electroclinical triad: a relentless mixture of multiple seizure types (most prominently generalized tonic seizures, atonic "drop" attacks, and atypical absences), moderate-to-profound cognitive impairment and developmental regression, and hallmark interictal electroencephalographic (EEG) abnormalities characterized by diffuse slow spike-and-wave (<3 Hz) complexes during wakefulness and generalized paroxysmal fast activity (GPFA) during sleep. Because the unrelenting seizure burden drives profound neurocognitive decline and carries a severe risk of trauma-related morbidity and premature mortality, the modern therapeutic paradigm demands an aggressive, multidisciplinary approach. Management universally requires complex polytherapy with broad-spectrum anti-seizure medications (ASMs)-frequently integrating agents specifically indicated for LGS such as clobazam, rufinamide, or highly purified cannabidiol-while heavily relying on non-pharmacological interventions, including the ketogenic diet, vagus nerve stimulation (VNS), and palliative surgical corpus callosotomy to specifically mitigate the devastating, life-threatening impact of atonic drop attacks.

Key Highlights

• In Germany, diagnosed Lennox-Gastaut Syndrome (LGS) cases are projected to increase from **6,787 in 2025 to 6,849 by 2035**.
• LGS is a rare, severe epileptic encephalopathy associated with multiple seizure types and cognitive impairment.
• Despite available antiseizure therapies, many patients continue to experience treatment-resistant seizures.
• Significant unmet need remains for therapies that provide sustained seizure control and improve quality of life.

Market Overview

• The Italy LGS market is projected to grow from **$50M in 2025 to $110M by 2035**.
• Market growth is driven by:
• Increasing adoption of novel antiseizure therapies
• Ongoing development of targeted treatment options
• Future growth will depend on therapies capable of achieving durable seizure reduction and improved patient outcomes.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Epygenix
• Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
• SK Life Science, Inc.
• NeuroPace
• Zogenix, Inc.
• Jazz Pharmaceuticals
• Longboard Pharmaceuticals

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)